About Liminatus Pharma, Inc. Warrants
https://liminatuspharma.comLiminatus Pharma, Inc. operates as a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is based in LA Palma, California.
CEO
Chris Kim
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public April 30, 2025
Method of going public SPAC
Full time employees 0
Ratings Snapshot
Rating : D+
Discounted Cash Flow 1
Return On Equity 1
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 1
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Market Cap $939169
52w High $0.04
52w Low $0.04
P/E 0
Volume 10.97K
Outstanding Shares 26.83M
About Liminatus Pharma, Inc. Warrants
https://liminatuspharma.comLiminatus Pharma, Inc. operates as a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is based in LA Palma, California.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $701.17K ▼ | $-1.82M ▼ | 0% | $-0.07 ▼ | $-1.8M ▼ |
| Q2-2025 | $0 | $1.12M ▲ | $113.29K ▲ | 0% | $0 ▲ | $176.32K ▲ |
| Q1-2025 | $0 | $260 ▼ | $-255 ▲ | 0% | $0 ▲ | $-255 ▲ |
| Q4-2024 | $0 | $522.79K ▼ | $-868.31K ▼ | 0% | $-0.12 ▼ | $-728.5K ▼ |
| Q3-2024 | $0 | $1.02M | $-642.9K | 0% | $-0.09 | $-637.74K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2024 | $804.54K ▲ | $2.83M ▼ | $18.7M ▼ | $-15.87M ▼ |
| Q3-2024 | $47K ▼ | $4.51M ▲ | $23.62M ▲ | $-14.25M ▼ |
| Q2-2024 | $339.2K ▲ | $3.54M ▲ | $16.61M ▼ | $-13.07M ▼ |
| Q1-2024 | $26K ▼ | $2.59M ▲ | $20.14M ▲ | $0 |
| Q4-2023 | $434K | $2.24M | $18.04M | $0 |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2024 | $-868.31K ▼ | $-785.5K ▼ | $-57.34K ▼ | $550K ▲ | $446.36K ▲ | $-785.5K ▼ |
| Q3-2024 | $-642.9K ▼ | $-729.36K ▼ | $485.53K ▼ | $262.8K ▲ | $18.98K ▲ | $-729.36K ▼ |
| Q2-2024 | $-534.85K ▲ | $-687.89K ▲ | $1.29M ▼ | $-465.67K ▼ | $-1.13M ▼ | $-687.89K ▲ |
| Q1-2024 | $-858.23M ▼ | $-903.72M ▼ | $248.83M ▲ | $700M ▼ | $45.11M ▲ | $-903.72M ▼ |
| Q4-2023 | $734.64M | $1.46B | $-11.43B | $9.91B | $-337.29M | $1.46B |
CEO
Chris Kim
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public April 30, 2025
Method of going public SPAC
Full time employees 0
Ratings Snapshot
Rating : D+
Discounted Cash Flow 1
Return On Equity 1
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 1
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0